Trial Profile

A Phase 2 Study of Dabrafenib and Trametinib in Combination With PDR001 in Patients With BRAFV600E Metastatic Colorectal Cancer

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dabrafenib (Primary) ; Spartalizumab (Primary) ; Trametinib (Primary)
Indications Colorectal cancer
Focus Adverse reactions; Proof of concept; Therapeutic Use

Most Recent Events

10 Apr 2024 Results presented at the 115th Annual Meeting of the American Association for Cancer Research
01 Feb 2023 Primary endpoint has been met. (Overall Response Rate), as per Results published in the Nature Medicine
01 Feb 2023 Status has been changed to completed, as per Results published in the Nature Medicine

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com